Dr. Reddy's Laboratories500124Pharmaceuticals
Analyst expects Dr. Reddy's Semaglutide manufacturing issue to be resolved by Q3, enabling resumption of supplies to Canada, with a biosimilar approval decision for Avastin expected in December
By ScoutQuest · · 1 min read
Heard on business television between 12:15:37 - 12:18:37 IST.
- Market seen focused only on near-term earnings for Dr. Reddy's
- Semaglutide manufacturing issue expected to be resolved by quarter three, allowing resumption of supplies to large markets like Canada
- Target action date for biosimilar of Avastin expected around December, described as a fairly large market opportunity
- Positive approval outcome could represent a large opportunity heading into FY28
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Dr Reddys Laboratories
Dr Reddy's files audio and video recordings of October 23, 2026 earnings call on Q2/H1 FY27 results
24 Oct 2026
Auditor's limited review reports with UDIN on Q2 and H1 results
23 Oct 2026
Board approves appointment of Akhil Ravi as Head API and Services and Senior Management Personnel
23 Oct 2026
Source: Live TV News Channel · 16 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.